Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Vinorelbine 2Paclitaxel 2Irinotecan 2temsirolimus 1taxane 1liposomal doxorubicin 1entinostat 1Trastuzumab 1Sirolimus 1Ritonavir 1Radiotherapy 1RRx-001 1Pemetrexed 1PM 01183 1Nivolumab 1Microscopy, Electron 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Gemcitabine 1Fentanyl 1Etoposide 1Cisplatin 1Carboplatin 1CYT-6091 1Bortezomib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × taxane × Endocrine × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡